US 10,716,591 · Application 15/785,897 · Granted Jul 21, 2020
US 10,716,591
Method and apparatus for tissue grafting
Estimated expiration
April 1, 2029
2y 206d remaining
Earliest effective filing
Apr 1, 2009
+ 20 years
Apr 1, 2029
PTA +0d
Apr 1, 2029
No TD
—
Final
Apr 1, 2029
This calculation includes patent term adjustment (PTA) under 35 U.S.C. §154(b). Patent term extension (PTE) under 35 U.S.C. §156 (for FDA-regulated products) is not included.
Calculation details
Base term
- Filing date
- October 17, 2017
- Earliest effective filing
- April 1, 2009
- Issue date
- July 21, 2020
- PTA
- 0 days
- Base expiry (before PTA)
- April 1, 2029
April 1, 2009 + 20 years = April 1, 2029
- Continuation of application 12/936,173, filed Oct 12, 2011, issued as US 9,827,006
- National stage entry of application PCTUS2009039114, filed Apr 1, 2009
- National stage entry of application PCTUS2009039114, filed Apr 1, 2009
- PRO61/041,587 — Provisional — not used for base term
- PRO61/041,587 — Provisional — not used for base term
- PRO61/041,587 — Provisional — not used for base term
Terminal disclaimers
Patent term extension under 35 U.S.C. §156, which can apply to certain drug, biologic, animal drug and medical device patents, is not included in this calculation. How PTE is calculated
The prosecution record for your AI
Application 15/785,897 · US 10,716,591
You have the date. Your AI can have the file.
PatentReply compiles the prosecution history behind US 10,716,591: the claims as filed and as allowed, every Office Action and response, and the cited references, with each answer pointing back to the filed passage.
One public application a month is free. The first compile takes a few minutes.
Strategy and filing changes require your approval.
Permanent link
www.patentreply.ai/tools/patent-expiration/US10716591Data sourced from public USPTO records. This tool provides informational estimates and should not be relied upon as legal advice. Always verify patent expiration dates independently, especially where patent term extension, terminal disclaimers, or unusual continuity issues may apply.